UroGen Pharma (URGN) Payables (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Payables data on file, last reported at $35.3 million in Q1 2026.

• Quarterly Payables rose 16.57% year-over-year to $35.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.3 million (up 16.57% YoY) and the FY2025 annual result came in at $27.7 million, up 1.04% from the prior year.
• Payables grew to $35.3 million in Q1 2026, from $27.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $35.3 million in Q1 2026 to a low of $8.6 million in Q2 2022.
• A 5-year average of $20.2 million and a median of $18.2 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables decreased 16.39% — and 2023, when it surged 89.7%.
• Tracing URGN's Payables over 5 years: stood at $12.4 million in 2022, then jumped by 33.55% to $16.5 million in 2023, then jumped by 65.87% to $27.4 million in 2024, then grew by 1.04% to $27.7 million in 2025, then increased by 27.52% to $35.3 million in 2026.
• The last three Payables figures came in at $35.3 million (Q1 2026), $27.7 million (Q4 2025), and $26.2 million (Q3 2025), per Business Quant data.